ARA-290 Half-Life, Stability and Pharmacokinetics in Research

Reviewed for accuracy by the Gorilla Research Labs research team · 2026-07-04

RESEARCH ARA-290 Half-Life, Stability and Pharmacokinetics in Research ARA-290 is an 11-amino acid peptide designed to target the innate repair receptor, though its precise half-life remains largely uncharacterized in publicly available pharmacokinetic literature. Current research focuses primarily on its clinical potential in neuropathic conditions rather than the granular details of its metabolic clearance. Compound identity: CAS 1208243-50-8 · C51H84N16O21 · 1257.3 g/mol (verified via PubChem)

The Architecture of ARA-290

ARA-290, also known as cibinetide, is a synthetic peptide engineered to mimic the tissue-protective properties of erythropoietin without triggering erythropoiesis. By specifically targeting the innate repair receptor (IRR), the compound aims to modulate inflammatory responses and promote tissue healing at the site of injury. Unlike its parent molecule, ARA-290 is purposefully stripped of the ability to stimulate red blood cell production, a design choice that shifts the research focus toward its neuroprotective and anti-inflammatory mechanisms.

Pharmacokinetic Ambiguity

In the landscape of peptide research, the half-life of a compound is a critical metric for understanding how long it remains active in a biological system. However, for ARA-290, the specific numerical half-life in human or animal models has not been definitively established in the primary literature. While researchers have utilized the compound in clinical settings, the pharmacokinetic profiles—specifically the time it takes for plasma concentration to reduce by half—remain an open question in the available data ^[1], ^[2]. Without standardized pharmacokinetic studies, researchers often rely on the observed duration of biological effects in trial settings to infer the compound's presence, rather than direct measurements of its metabolic decay.

Evidence from Clinical Observations

The clinical utility of ARA-290 has been explored in human trials, most notably in the context of small-fiber neuropathy and type 2 diabetes ^[1], ^[2]. In a randomized pilot study involving patients with sarcoidosis-associated small-fiber neuropathy, ARA-290 was administered to evaluate its impact on neuropathic pain and nerve fiber density ^[1]. Similarly, a phase 2 study investigated its efficacy in patients with type 2 diabetes suffering from painful neuropathy ^[2]. While these studies provide valuable data on the physiological outcomes and safety profiles of the peptide, they do not offer the detailed pharmacokinetic modeling required to define its half-life or stability under varying environmental conditions ^[1], ^[2].

Stability and Formulation Considerations

Peptide stability is a function of both the molecular structure and the environment in which the compound is stored. Because ARA-290 is a synthetic peptide, it is inherently susceptible to degradation via hydrolysis and enzymatic cleavage if not managed under controlled conditions. The stability of ARA-290 in various solvents or temperatures has not been characterized in the primary literature ^[1], ^[2]. Standard laboratory practice for synthetic peptides involves storage in controlled, low-temperature environments to mitigate potential degradation ^[1], ^[2].

What the Research Does Not Define

It is crucial to distinguish between the clinical findings reported in literature and the missing data regarding the compound's fundamental kinetics. The existing literature does not provide a peak plasma concentration (Tmax) or a volume of distribution for ARA-290 ^[1], ^[2]. Furthermore, there is no evidence regarding the metabolic pathways—such as renal or hepatic clearance—that govern the elimination of the peptide from the body. These gaps mean that any discussion regarding the "optimal" timing or frequency of administration remains speculative and unsupported by the current body of research ^[1], ^[2].

Frequently asked questions

What is the half-life of ARA-290? The half-life of ARA-290 is not established in the available scientific literature. While the compound has been used in human clinical trials, researchers have not published specific pharmacokinetic data defining its half-life ^[1], ^[2]. Is ARA-290 stable at room temperature? There is no publicly available data regarding the stability of ARA-290 at room temperature. Standard research practice for synthetic peptides involves storage in controlled, low-temperature environments to mitigate the risk of degradation. Does the research define how ARA-290 is metabolized? The current body of research does not define the metabolic pathways for ARA-290. While its mechanism of action involves the innate repair receptor, the specific processes of how the body breaks down and eliminates the peptide are not identified in the cited studies ^[1], ^[2]. Are there human studies confirming the pharmacokinetics of ARA-290? No. While human trials have been conducted to assess the therapeutic potential of ARA-290 in neuropathic conditions, these studies focused on clinical outcomes rather than pharmacokinetic modeling ^[1], ^[2]. How do researchers ensure the quality of ARA-290? Researchers verify the quality of synthetic peptides by requesting a Certificate of Analysis (COA) from suppliers. This document typically includes data from high-performance liquid chromatography (HPLC) to confirm purity and mass spectrometry to verify the molecular weight, ensuring the material matches the intended sequence. When selecting research materials, the scientific community relies on transparency and rigorous verification. High-quality research depends on the procurement of peptides that come with batch-specific documentation, including a Certificate of Analysis (COA) that details purity levels and impurity profiles. By utilizing lot-tracking and independent analytical testing, researchers ensure that the material used in their experiments is consistent, stable, and accurately represented, allowing for the reproducibility that is the hallmark of sound scientific inquiry. Research use only. The compounds discussed are supplied for laboratory research and are not for human or veterinary use. Nothing on this page is medical advice, a dosing guide, or a claim about any product sold here; it summarises published research and cites its sources.